S.

NO DRUG MECHANISM OF ACTION SPECIFICALLY INDICATED IN DOSAGE COST

FOR ANTI CRAVING

1. BACLOFEN GABA-B AGONIST. PHYSICAL WORK (AS A MUSCLE RELAXANT) 10 MG TID 208.25/- FOR 10
(BACFEN XL 20MG) FAMILY ISSUES, CAPSULES.
LIOFEN XL DECREASES THE USE OF BENZODIAZEPINES. 20MG TID

(EMOTIONAL AND STRESS FUL CONSUMPTION).

2. ACAMPROSATE GLUTAMATERGIC NMDA ANTAGONIST AND GERIATRIC DRINKERS. 666 MG 68.85/- FOR 6 TABLETS.
(ACT AS ARTIFICIAL TID(>60KG)
ALCOHOL) INCREASES GABA- ERGIC FUNCTION.
(ACAMPROL (DECREASES DESIRE AND QUANTITY OF DRUG. 666 MG BD(<60KG)
333MG) MODULATORY EFFECT ON THE GLUTAMATERGIC NEUROTRANSMISSION AND
PREDOMINANTLY COUNTERACT HYPER-GLUTAMATERGIC STATES.

3. NALTREXONE BLOCKS MU OPIOID RECEPTORS. GERIATRIC DRINKERS AND ASSOCIATED WITH OTHER UPTO 100 MG PER 651/- FOR 10 TABLETS.
(NODICT 50 MG) SUBSTANCES. DAY AFTER
MODULATION OF OPIOID SYSTEMS, THERE BY REDUCING THE ABTINENCE FOR 3
REINFORCEMENT EFFECTS OF ALCOHOL. (DECREASES THE EFFECT OF ABUSED DRUG). TO 5 DAYS.

4. CARBAMAZEPINE GLUTAMATE, VOLTAGE-GATED SODIUM AND CALCIUM CHANNEL BLOCKER 14.71/-,28.48/-,

(ZEPTOL-CR (GLU-CB) IMPULSIVE DRINKERS, 28.9/-
200/300/400 MG) AGITATION, FOR 10 TABLETS ?
SUPPRESSING THE WITHDRAWAL INDUCED KINDLING THAT OCCURS NARCISSISTIC,
WITH A H/O BAD PARENTING, ADHD, ANTI-SOCIAL PD.
RETURN TO DRINKING; AND IMPROVEMENT IN THE PHENOMENA OF
PROTRACTED WITHDRAWAL, FOR WHOM DETOXIFICATION FAILED IN THE PAST.
ESPECIALLY MOOD.IMPROVE THE QUALITY OF PEOPLE'S RECOVERY AND
REMOVE POTENTIAL TRIGGERS TO RELAPSE.
5. TOPIRAMATE FACILITATION OF GABA ACTIVITY AND INHIBITION OF GLUTAMATE BINGE DRINKING PATTERNS. 25 MG/DAY 68.85,109.65/-,194.65/-
(TOPIROL FUNCTION. TITRATED OVER 8 FOR 10 TABLETS.
25/50/100) WEEKS UP TO 300
SUPPRESSING CORTICO-MESOLIMBIC DOPAMINE RELEASE. MG/DAY.

6. DISULFIRAM INTERFERE WITH ACETALDEHYDE DEHYDROGENASE. NON-CO-OPERATIVE DRINKERS. 125-500MG PER 22.53 /- FOR 10
DAY TABLETS
ALCOHOL-DISULFIRAM REACTION. (AVERSION THERAPY)

7. FLUOXETINE SELECTIVE SEROTONIN REUPTAKE INHIBITOR. COMPULSIVE DRINKERS, OCD, LOVE FAILURE. 20 TO 40 MG PER 22/-,35.7/-,48.02/-,67.1
(FLOATIN DAY OVER 12 5/-.
10/20/40/60 MG) USED WITH COMORBID PSYCHIATRIC ILLNESS. (USED IN OBSESSIVE ADDICTION). WEEKS.

8. QUETIAPINE 5-HT2A AND D2 ANTAGONISM ON THE MESOLIMBIC DOPAMINERGIC 60.35/-,75.65/-,127.5/-,

(QUITIPIN SR PATHWAY INTO THE NUCLEUS ACCUMBENS. PSYCHOTIC DRINKERS (AIMLESS, GOAL LESS) 173.4/-,226.95/-.
50/100/200/300/
400 MG) 5-HT2A ANTAGONISM MODULATES THE ACTIVITY OF DOPAMINERGIC
NEURONS DIFFERENTIALLY IN THE MESOCORTICAL AREAS.

BLUNTING THE REINFORCING EFFECTS OF ALCOHOL AND DAMPENING

ALCOHOL CRAVING.

9. ONDANSETRON MODULATING DOPAMINE RELEASE IN MESOCORTICOLIMBIC DOPAMINE EARLY ONSET ALCOHOLICS. 4 MICRO GM/KG
PATHWAYS. BD

(NOT AVAILABLE
AT THESE DOSES)